Consolidated figures · ₹ crore
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 125 | 128 | 74 | 74 | 78 | 127 | 157 | 222 | 240 | |
| COGS | 79 | 45 | 31 | 9 | 11 | 6 | 9 | 9 | 16 |
| Gross profit | 47 | 83 | 43 | 64 | 67 | 121 | 148 | 213 | 224 |
| -86 | -125 | -197 | -276 | -83 | -29 | -84 | -47 | -58 | |
| 132 | 208 | 239 | 340 | 150 | 150 | 233 | 260 | 282 | |
| OPM % | 105.6% | 162.9% | 323.8% | 462.6% | 191.5% | 118.2% | 147.7% | 117.1% | 117.5% |
| Depreciation | 4 | 3 | 3 | 4 | 5 | 7 | 8 | 11 | 12 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| 37 | 29 | 93 | 10 | 89 | 54 | 55 | 75 | 73 | |
| Profit before tax | 165 | 235 | 329 | 346 | 234 | 197 | 278 | 322 | 340 |
| Tax | 2 | 4 | 0 | 3 | 12 | 6 | 10 | 11 | 23 |
| Tax % | 1.5% | 1.8% | 0% | 0.9% | 5% | 3.1% | 3.5% | 3.4% | 6.7% |
| 163 | 230 | 329 | 343 | 222 | 191 | 269 | 311 | 317 | |
| PAT margin % | 130.1% | 180.4% | 445.2% | 466.3% | 283.9% | 149.8% | 170.6% | 140% | 132.3% |
| EPS (₹) | 6.1 | 8.9 | 12.8 | 13.4 | 8.7 | 7.4 | 10.5 | 12.1 | 12.4 |
| EPS adjusted (₹) | 6.1 | 9 | 12.8 | 13.4 | 8.7 | 7.4 | 10.5 | 12.1 | 9 |
| 3.3% | 2.2% | 4.7% | 1.5% | 20.8% | 29.6% | 22.9% | 19.8% | 19.4% | |
| Annual report | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 53 | 53 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 |
| Reserves | 858 | 1,032 | — | 1,367 | 2,246 | 2,445 | 2,027 | 2,134 | 2,287 | 2,394 |
| — | — | — | 0 | 0 | 0 | 0 | 9 | 14 | 11 | |
| 81 | 73 | — | 53 | 112 | 135 | 127 | 134 | 150 | 134 | |
| Total equity & liabilities | 992 | 1,159 | — | 1,471 | 2,409 | 2,632 | 2,205 | 2,329 | 2,503 | 2,590 |
| — | — | 131 | 131 | 134 | 134 | 132 | 131 | 135 | 170 | |
| CWIP | 0 | — | — | 3 | 6 | 0 | 0 | 1 | 0 | 2 |
| Investments | 178 | 237 | — | 1,227 | 2,178 | 2,372 | 1,943 | 2,024 | 2,174 | 2,276 |
| 815 | 922 | — | 110 | 91 | 127 | 130 | 173 | 194 | 142 | |
| Total assets | 992 | 1,159 | — | 1,471 | 2,409 | 2,632 | 2,205 | 2,329 | 2,503 | 2,590 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Real Estate Business | 193.4 | 81.17 | 515.78 | 81.48 | 434.3 | 18.69 |
| Active Pharmaceutical Ingredients Business | 46.59 | 5.65 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 52 | 24 | 22 | 7 | -2 | -18 | 39 | 23 | 86 | 120 | |
| -47 | -22 | 72 | 57 | -35 | 19 | 7 | 26 | -27 | -54 | |
| -5 | -3 | -89 | -6 | -15 | -6 | -46 | -48 | -58 | -68 | |
| Net cash flow | -0 | -1 | 1 | 57 | -52 | -5 | -0 | 0 | 1 | -1 |
| Free cash flow | — | — | — | -16 | -10 | -19 | 39 | 21 | 80 | 82 |
| CFO / Operating profit % | — | 212.2% | 102.4% | 198.8% | -19.7% | -127.4% | 96.3% | 39.9% | 92.2% | 132.7% |
| 180.81 |
| 34.8 |
| 146.01 |
| 3.87 |
₹ crore by fiscal year